Theraclone Sciences has completed the dosing of the first patient in a randomised, double-blind, dose-escalation Phase I trial to investigate TCN-032 as a treatment for influenza A virus.
The trial is supported in part by Theraclone’s multi-year R&D agreement with Zenyaku Kogyo to identify conserved, essential antibody targets and develop candidates for the treatment of pandemic and severe seasonal influenza.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
TCN-032 was discovered using Theraclone’s I-STAR platform.
The Phase I study will enrol up to 40 healthy adult volunteers to assess the safety profile of a single intravenous administration of TCN-032 compared to placebo.
The study will also provide pharmacokinetic and immunogenicity data.
Study results are expected in the first half of 2012 and are required for commencement of proof-of-concept clinical trials.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData
